Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about HCRTR1/HCRTR2: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | HCRTR1/HCRTR2 |
| Key Genes/Proteins | AQP1, AQP4, GJA1, HCRTR1, KCNK2, LOX |
| Related Diseases | neurodegeneration |
graph TD
HCRTR1_HCRTR2[HCRTR1/HCRTR2]
HCRTR1_HCRTR2 -->|promoted: Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation| neurodegeneration[neurodegeneration]
HCRTR1_HCRTR2 -->|debate_co_mention| KCNK2[KCNK2]
HCRTR1_HCRTR2 -->|debate_co_mention| LOX[LOX]
HCRTR1_HCRTR2 -->|debate_co_mention| LOX_LOXL1_4[LOX/LOXL1-4]
HCRTR1_HCRTR2 -->|debate_co_mention| PDGFRB[PDGFRB]
HCRTR1_HCRTR2 -->|co_associated_with| SDC1[SDC1]
HCRTR1_HCRTR2 -->|data_in| benchmark_ot_ad_answer_key_HCR[benchmark_ot_ad_answer_key:HCRTR1/HCRTR2]
AQP1[AQP1] -->|debate_co_mention| HCRTR1_HCRTR2
AQP4[AQP4] -->|debate_co_mention| HCRTR1_HCRTR2
GJA1[GJA1] -->|debate_co_mention| HCRTR1_HCRTR2
HCRTR1[HCRTR1] -->|debate_co_mention| HCRTR1_HCRTR2
benchmark_ot_ad_answer_key_HCR -->|data_in| HCRTR1_HCRTR2| Target | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:HCRTR1/HCRTR2 | data_in | dataset_row | 0.00 |
| neurodegeneration | associated_with | disease | 0.60 |
| KCNK2 | debate_co_mention | gene | 0.45 |
| LOX | debate_co_mention | gene | 0.45 |
| LOX/LOXL1-4 | debate_co_mention | gene | 0.45 |
| PDGFRB | debate_co_mention | gene | 0.45 |
| KCNK2 | co_associated_with | gene | 0.40 |
| SDC1 | co_associated_with | gene | 0.40 |
| LOX/LOXL1-4 | co_associated_with | gene | 0.40 |
| PDGFRB | co_associated_with | gene | 0.40 |
| Source | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:HCRTR1/HCRTR2 | data_in | dataset_row | 0.00 |
| SUVOREXANT | inhibits | drug | 0.90 |
| SUVOREXANT | regulates | drug | 0.90 |
| AQP1 | debate_co_mention | gene | 0.45 |
| AQP4 | debate_co_mention | gene | 0.45 |
| GJA1 | debate_co_mention | gene | 0.45 |
| HCRTR1 | debate_co_mention | gene | 0.45 |
| AQP1 | co_associated_with | gene | 0.40 |
| GJA1 | co_associated_with | gene | 0.40 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Circadian Glymphatic Entrainment via Targeted Orexin Recepto | 0.882 | neurodegeneration | Perivascular spaces and glymphatic clear |
| Chronotherapeutic Orexin Modulation for Tau Clearance | 0.000 | - | Sleep disruption as cause and consequenc |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 14 hypotheses Top: 0.882
neurodegeneration | 2026-04-01 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,900,000 |
| DLB Cognitive Fluctuation Mechanism Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Circadian Dysfunction as Driver of Neurodegeneration | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep Disruption and Alzheimer's Disease — mechanism and intervention | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Respiratory Network Interaction in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868] | Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X | Pharmacol Rep | 2025 | 1 |
| Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662] | Dashti HS, Daghlas I, Lane JM, Huang Y, | Nat Commun | 2021 | 1 |
| Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813] | Sun Y, Tisdale RK, Kilduff TS | Front Neurol Neurosci | 2021 | 1 |
| Sleep drives metabolite clearance from the adult brain. [PMID:24136970] | Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th | Science | 2013 | 1 |
| Signal transduction, dimerization, and therapeutic targeting of Orexin and recep [PMID:41383480] | Zhang S, Wang P, Ji B, Shao Y, Hou S et | Front Pharmacol | 2025 | 0 |
| Bioinformatic analysis of neuropeptide related genes in patients diagnosed with [PMID:39437604] | Yay F, Ayan D | Comput Biol Med | 2024 | 0 |
| Effects of Paradoxical Sleep Deprivation on MCH and Hypocretin Systems. [PMID:39698172] | Agamme ALDA, Tufik S, Torterolo P, D'Alm | Sleep science (Sao Paulo, Braz | 2024 | 0 |
| Blast Exposure Induces Acute Alterations in Circadian Clock Genes in the Hypotha [PMID:41127649] | Govindarajulu M, Patel MY, Krishnan J, L | Neurotrauma reports | 2023 | 0 |
| Contextual generalization of social stress learning is modulated by orexin recep [PMID:35724928] | Yaeger JDW, Krupp KT, Summers TR, Summer | Neuropharmacology | 2022 | 0 |
| Evaluation of the α-casein (CSN1S1) locus as a potential target for a site-speci [PMID:35568783] | ["Smirnov A", "Kontsevaya G", "Shnaider | Scientific reports | 2022 | 0 |
| Outcomes of a telemedicine bowel management program during COVID-19. [PMID:34686377] | ["Knaus M", "Ahmad H", "Metzger G", "Bey | Journal of pediatric surgery | 2022 | 0 |
| Sleep interventions in AD trials show inconsistent cognitive benefits, possibly [PMID:33661831] | Unknown | Sleep Medicine Reviews | 2021 | 0 |
| Machine learning for clinical decision support in infectious diseases: a narrati [PMID:31539636] | ["Peiffer-Smadja N", "Rawson T", "Ahmad | Clinical microbiology and infe | 2020 | 0 |
| Complexities of Understanding Function from CKD-Associated DNA Variants. [PMID:32513823] | ["Lin J", "Susztak K"] | Clinical journal of the Americ | 2020 | 0 |
| Prostaglandin D [PMID:30513028] | ["Marone G", "Galdiero M", "Pecoraro A", | Expert opinion on investigatio | 2019 | 0 |
| CF-PA [PMID:31852950] | ["Morishita R", "Sugiyama S", "Denda M", | Scientific reports | 2019 | 0 |
| Transitions from Single- to Multi-Locus Processes during Speciation with Gene Fl [PMID:29795050] | ["Schilling M", "Mullen S", "Kronforst M | Genes | 2018 | 0 |
| Co-occurring expression and methylation QTLs allow detection of common causal va [PMID:29476079] | ["Pierce B", "Tong L", "Argos M", "Deman | Nature communications | 2018 | 0 |
| T-Cell Mediation of Pregnancy Analgesia Affecting Chronic Pain in Mice. [PMID:28877966] | ["Rosen S", "Ham B", "Drouin S", "Boachi | The Journal of neuroscience : | 2017 | 0 |
| Pentylenetetrazol-induced seizures are exacerbated by sleep deprivation through [PMID:23852314] | Ni LY, Zhu MJ, Song Y, Liu XM, Tang JY | Neurol Sci | 2014 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.95 · 2026-04-06
closed · Rounds: 4 · Score: 0.93 · 2026-04-01
Hypotheses and analyses mentioning HCRTR1/HCRTR2 in their description or question text
No additional research found